At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
18F-PSMAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy
In Brief
A Phase 2 clinical trial evaluating 18F-PSMA for Prostatic Neoplasms and 6 related conditions. Completed, enrolled 62 participants across 1 site.
Detailed Summary
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI in patients considered candidates for focal HIFU.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Genital Diseases, Male, Prostatic Disease
CountriesUnited States
CollaboratorsProgenics Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartApr 2021
Primary CompletionSep 2024
TodayJul 2026
First PostedJul 8, 2020
Enrollment StartApr 6, 2021
Primary CompletionSep 3, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.0 years ago
Interventions
18F-PSMAdrug
Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA) Other Names: 18F-DCFPyL Injection prostate-cancer-specific radiotracer